KTOV - Kitov Pharma reports new data for NT219's mechanism of action

Kitov Pharma (KTOV) has announced new mechanism of action data of NT219, a dual inhibitor, small molecule targeting IRS1/2 and STAT3. Data were presented at the Epigenetics and Metabolism AACR Special Virtual Conference at Tel-Aviv University.The new data demonstrates IRS2-amplified colorectal cancer ((CRC)) cells upregulate ?-catenin expression, and treatment with NT219 significantly decreased the ?-catenin transcriptional activity in these cells. Also, NT219 markedly inhibited cell viability in a dose-dependent manner.Data suggest that AKT and ?-catenin pathways downstream of IRS2 may be involved in mediating the aggressive phenotype of IRS2-amplified CRC cells in the brain microenvironment. Besides cellular proliferation via protein stabilization to promote cellular growth, Wnt/ ?-catenin has demonstrated a role in the establishment of the blood brain barrier and impacts the tumor microenvironment, associated with the therapeutic resistance of cancer cells.The drug candidate is currently enrolling patients in Phase 1/2 trial of NT219 as monotherapy for advanced solid tumors,

For further details see:

Kitov Pharma reports new data for NT219's mechanism of action